DPX-Survivac: Additional Phase I data

Data from 30 patients with stage IIc-IV advanced or recurrent ovarian cancer in the open-label, dose-ranging Phase I/Ib portion of a North American Phase I/II trial showed that subcutaneous DPX-Survivac in combination with low-dose oral cyclophosphamide led to 1 partial response defined as tumor shrinkage of >=30%. The response persisted following discontinuation of treatment and occurred in a patient with residual disease following platinum therapy. Additionally, Immunovaccine said the patient achieved a reduction in CA-125 levels and a significant increase in vaccine-induced immune responses. DPX-Survivac was well tolerated with no significant systemic adverse events reported. Data will be presented at the American Society of Clinical Oncology meeting in Chicago. ...